ORN-101, an optimized development-stage in situ CAR program, shows tumor eradication in a mouse model at doses far lower than previously reported results Orna's FoRCE screening platform has enabled ...
Financing accelerates clinical validation and commercial readiness, as circular RNAs emerge as a new category of brain-derived blood biomarkers with best-in-class performance SAN DIEGO, Dec. 1, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results